Mankind Pharma Ltd: History, Latest Updates, Milestones, Subsidiaries, and Share Price
INTRODUCTION
Mankind Pharma Ltd. is one of India’s leading pharmaceutical companies, founded in 1995, with a strong presence in domestic and international markets. Known for its diverse portfolio spanning prescription drugs, over-the-counter products, and healthcare solutions, the company has consistently focused on innovation, affordability, and accessibility. Over the years, Mankind Pharma has achieved several milestones, expanded through subsidiaries, and strengthened its distribution network across India and abroad. Investors often keep a close watch on the Mankind Pharma share price, which reflects the company’s robust growth, operational performance, and evolving presence in the pharmaceutical sector.
Mankind Pharma Ltd moves in 2025:
- Achieved annual revenue growth of around 10% in FY25, with topline reaching about Rs. 12,207?Cr compared to Rs. 11,110?Cr in FY24.
- Net profit for FY25 stood at nearly Rs. 2,006?Cr, supported by steady performance in chronic therapies and domestic sales.
- Earnings per Share (EPS) was reported at Rs. 40.47 in FY25.
- For Q1 FY26 (ended June 30, 2025), consolidated revenue rose 23.02% YoY to Rs. 3,650.23?Cr, while net profit declined 18.30% YoY to Rs. 438.32?Cr due to higher material and operational expenses.
- For Q2 FY26 (ended September 30, 2025), consolidated revenue increased 19.51% YoY to Rs. 3,789.03?Cr, while net profit fell 21.05% YoY to Rs. 520.18?Cr.
- The company maintained strong fundamentals with P/E of 54.64, EPS of Rs. 40.47, and cash reserves of Rs. 305.87?Cr.
- Investors closely track the Mankind Pharma share price, reflecting revenue growth, quarterly profit trends, and overall market performance.
Evolution of Mankind Pharma Ltd: From Past to Present:
Past:
Mankind Pharma was founded in 1991 and began operations in 1995 with a small team and modest capital. Initially, it focused on affordable medicines for rural India, particularly generics and antibacterials. In 2005, Mankind Pharma established its inaugural manufacturing unit at Paonta Sahib in Himachal Pradesh, marking a major milestone in its expansion journey. In the mid-2000s, Mankind expanded into consumer healthcare and OTC products, marking its transformation from a small pharma firm to a broader healthcare company.
Present:
Today, Mankind Pharma is one of India’s largest pharmaceutical companies, with over 23,000 employees and 1,000+ approved products across prescription, OTC, and wellness segments. It operates 30+ manufacturing units and R&D facilities, and has grown through strategic acquisitions, including Bharat Serums and Vaccines. The company leverages modern technology in manufacturing, supply chain, and distribution, maintaining a strong presence in urban and rural markets across India.
| Name | Mankind Pharma Ltd |
| Founded year | 1991 |
| Key People | Ramesh Juneja (Chairman) Rajeev Juneja (MD & Vice Chairman) Sheetal Arora (CEO) Arjun Juneja (COO) |
| Subsidiaries | Bharat Serums and Vaccines Limited (BSV) Mankind Agritech Private Limited Mankind Prime Labs Private Limited Mankind Life Sciences Private Limited Broadway Hospitality Services Private Limited Appian Properties Private Limited Pavi Buildwell Private Limited Penta Latex LLP Medipark Innovations Private Limited |
| Headquarters | Delhi, India |
| Sector | Pharmaceutical |
| Nse code | MANKIND |
| Bse code | 543904 |
Timeline of Mankind Pharma Ltd :
| Year | Major Events & Milestones |
| 1991 | Mankind Pharma Private Limited was officially established on July 3, marking the beginning of its pharmaceutical journey. |
| 2004 | Made its entry into the chronic therapy space with notable launches such as Amlokind and Glimestar. |
| 2005 | Transitioned into a Public Limited Company and commissioned its first manufacturing plant at Paonta Sahib, Himachal Pradesh. |
| 2007 | Expanded into consumer healthcare with the launch of the Manforce brand; also ventured into animal health with Bandykind and Ceftiforce. |
| 2009 | Added a second production unit at Paonta Sahib to support growing operations. |
| 2010 | Introduced Preganews, strengthening its consumer healthcare portfolio. |
| 2012 | Established its first dedicated research and development centre at IMT Manesar, Haryana. |
| 2014 | Acquired Shree Jee Laboratory Pvt. Ltd., along with its API facility located in Behror, Rajasthan. |
| 2015 | Set up international subsidiaries—Lifestar Pharma LLC in the U.S. and Mankind Pharma Pte. Ltd. in Singapore. |
| 2017 | Expanded its manufacturing footprint with a new facility in Sikkim. |
| 2019 | Entered the female infertility therapeutic segment with the launch of Dydroboon. |
| 2020 | Formed Lifestar Pharmaceuticals Pvt. Ltd. in Nepal; launched key cardiovascular drugs such as Cilaheart and Statpure, and diabetes formulation Zukanorm. |
| 2021 | Added Mankind Pharma FZ-LLC in Dubai; introduced respiratory drug Mlife and neuro/CNS therapies including Trugaba-NT and Prebris-MNT. |
| 2022 | Purchased select brands from Panacea Biotec (India and Nepal); ventured into transplant care (Pangraf, Mycept) and oncology (Pacliall); acquired Daffy and Combihale from Dr. Reddy’s. |
| 2022 | Operated 23 manufacturing sites with a combined installed annual capacity of 40.77 billion units. |
| April 2023 | Completed its IPO, offloading 40,058,844 equity shares and raising ?4,326.35 crore through an Offer for Sale. |
| FY 2022–23 | Took over 90% of Upakarma Ayurveda Pvt. Ltd., fully acquired Mankind Agritech Pvt. Ltd., secured a 6.3% stake in Actimed Therapeutics, and merged Lifestar Pharma Pvt. Ltd. & Magnet Labs Pvt. Ltd. into the parent company. |
| 2023–24 | Formed Mankind Medicare Private Limited as a wholly owned subsidiary. |
| April 2024 | Divested its OTC business to Mankind Consumer Products Pvt. Ltd. through a slump sale. |
| October 2024 | Acquired Bharat Serums and Vaccines Ltd. (BSV), making it a 100% subsidiary. |
| 2025 | Rolled out a dedicated Urology Specialty Division to strengthen its specialty care portfolio. |
Inside Mankind Pharma Ltd and its Subsidiaries:
Mankind Pharma Ltd
Corporate actions:As of 04 December 2025, the mankind pharma share price is around Rs. 2,205.70. In the past year, the company has declared a single equity dividend of Rs. 1.00 per share, issued as an interim payout on 08 August 2025, with the same date as the record date. Based on the current price, this results in a modest dividend yield of 0.05%, reflecting limited but consistent shareholder returns.
Main News:
- November 2025
In November, Mankind Pharma reported a 21% decline in its Q2FY26 net profit, dropping to Rs. 458.90 crore, while total income inched up 1.31% to Rs. 2,686.45 crore.The softer quarterly numbers created cautious sentiment, though long-term fundamentals continued to lend support to the mankind pharma share price.
- October 2025
In October, the company signed a Business Transfer Agreement with its subsidiary BSV to acquire the Women Health Rx Portfolio for Rs. 797 crore via a slump sale.
- August 2025
In August, Mankind Pharma established a wholly owned subsidiary in Russia, named Mankind Pharma LLC, to distribute pharmaceutical products from BSV, marking a strategic international push. The company also posted an 18% decline in Q1FY26 net profit to Rs. 412.76 crore, though income grew 3.86%, offering mixed indicators for investors tracking the mankind pharma share price.
- June 2025
In June, ISS ESG released a voluntary ESG Corporate Rating Report, assigning Mankind Pharma an overall ESG score of 38.98 (Rating: C-).
Bharat Serums and Vaccines Limited (BSV)
In October 2025, Mankind Pharma signed a Business Transfer Agreement with BSV to acquire its Women’s Health Rx Portfolio for Rs. 797 crore through a slump sale. The amount will be paid in two stages—half at closing and the rest within 150 days. This move shifts the portfolio directly under Mankind Pharma, strengthening its position in the women’s health segment.
Mankind Agritech Private Limited
As of November 2025, Mankind Agritech Private Limited remains a fully consolidated subsidiary, with no new public business updates in the last three months. Its continued consolidation reflects its ongoing role within the group’s structure.
Mankind Prime Labs Private Limited
Mankind Prime Labs also continues as a fully consolidated subsidiary as per the latest disclosures from November 2025. No recent standalone developments have been reported, but it remains part of the company’s operational framework.
Current Mankind Pharma Share Price NSE:
| COMPANY NAME | SECTOR | SHARE PRICE LINK |
| Mankind Pharma Ltd | PHARMACEUTICALS | Mankind Pharma Stock Price |
Achievements and Milestones:
Over the years, the company has earned several prestigious awards across healthcare, branding, innovation, and marketing, reflecting its strong industry presence and consumer trust.
| Year | Awards & Recognitions |
| 2024 | ET Awards – Entrepreneur of the Year; The Indian Brand and Leadership Conclave – Most Trusted Brand of the Nation (PregaNews) |
| 2023 | Won the e4m Pride of India Brands, Best of Bharat, and Best of North awards; recognised as the Most Innovative Green Healthcare Company; and received the Healthcare Innovation Excellence Award for PregaNews’ Shakti Awareness Program. |
| 2022 | e4m Pride of India Brands; The Best of Bharat Awards; IHW Awards – Good Health Brand |
| 2016 | Sox Brand Awards – Best Condom Brand of the Year (Manforce); Afaqs Award – India’s Busiest Brand (Manforce) |
CONCLUSION
In conclusion, Mankind Pharma Ltd has transformed from a modest, rural-centric drug maker into a major force in India’s pharmaceutical landscape. With a wide-ranging portfolio that includes prescription medicines, OTC brands, and specialty therapies, the company has expanded steadily through strong financial performance, targeted acquisitions, continuous innovation, and a widening international footprint. For investors, the Mankind Pharma share price mirrors the company’s solid fundamentals and its long-term growth potential across chronic care, consumer health, and high-value specialty segments.
To check Mankind Pharmaceuticals share price and explore detailed stock analysis, visit Enrich Money. It also provides a free demat account with no annual maintenance fees, positioning it as one of the best stock trading apps for beginners in India.
Frequently Asked Questions:
Where can I find real-time updates on the Mankind Pharma share price?
Check the latest share price of Mankind Pharma and live stock updates on Enrich Money’s stock here.
How has the Mankind Pharma share price moved in the last 12 months?
The 52-week high of Mankind Pharma stock price is Rs. 3,054.80, while the 52-week low of Amara Raja Batteries share price is Rs.
2,115.10.
Is the Mankind Pharma share price affected by the company’s acquisitions and expansions?
Yes, strategic moves like acquiring Bharat Serums & Vaccines, Upakarma Ayurveda, and entering international markets help shape the outlook of the Mankind Pharma share price.
How much dividend yield does the Mankind Pharma share price offer?
Based on the current Mankind Pharma share price, the dividend yield is approximately 0.05%, reflecting modest but consistent returns for shareholders.
What is the market capitalization based on Mankind Pharma share price?
Based on the current Mankind Pharma share price, the company has a market capitalization of approximately Rs. 91,048.29?Cr.
What are the P/E and P/B ratios of Mankind Pharma share price?
The P/E ratio of Mankind Pharma is 54.50, and the P/B ratio is 5.87, indicating the stock’s valuation relative to earnings and book value according to the current share price of Mankind Pharma.
Check our ORCA app to analyze stocks' performance:
- Mankind Pharma share price
- Mankind Pharma Technical Analysis
- Mankind Pharma Future Price
- Mankind Pharma Financial Statements
- Mankind Pharma Shareholding Pattern
- Mankind Pharma Share Price News
- Mankind Pharma Overview
Related Stocks
Disclaimer: This blog is dedicated exclusively for educational purposes. Please note that the securities and investments mentioned here are provided for informative purposes only and should not be construed as recommendations. Kindly ensure thorough research prior to making any investment decisions. Participation in the securities market carries inherent risks, and it's important to carefully review all associated documents before committing to investments. Please be aware that the attainment of investment objectives is not guaranteed. It's important to note that the past performance of securities and instruments does not reliably predict future performance.
